BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2692448)

  • 1. [Clinical application of immunoenzyme assay for prostatic acid phosphatase].
    Yoshida K; Sato S; Nishimura T; Akimoto M
    Hinyokika Kiyo; 1989 Oct; 35(10):1819-22. PubMed ID: 2692448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostatic acid phosphatase by enzymeimmunoassay].
    Masukagami T; Ando K; Shimazaki J
    Hinyokika Kiyo; 1984 Nov; 30(11):1691-5. PubMed ID: 6084950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of serum prostatic acid phosphatase assay based on the immunoenzymatic method (TZR-516)].
    Ikemoto I; Machida T; Oishi Y; Onishi T; Shirai T; Imanaka K
    Hinyokika Kiyo; 1989 Sep; 35(9):1639-42. PubMed ID: 2479240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of a monoclonal antibody-based enzyme immunoassay (IQ(Bio) PAP-AELIA kit) for prostatic acid phosphatase].
    Koshida K; Naito K; Hisazumi H
    Hinyokika Kiyo; 1987 Oct; 33(10):1703-7. PubMed ID: 3328502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer].
    Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improved diagnostic evaluation of prostatic neoplasms using radioimmunoassay for prostatic acid phosphatase].
    Gaca A; Panitz N
    Helv Chir Acta; 1981 Aug; 48(3-4):465-6. PubMed ID: 7287485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer].
    Watanabe M; Kitamura Y; Komatsubara S; Sakata Y
    Hinyokika Kiyo; 1988 Dec; 34(12):2135-41. PubMed ID: 2467542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate specific antigen in serum of the patients with prostatic cancer].
    Akimoto S; Akakura K; Fuse H; Shimazaki J
    Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
    Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
    Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prostatic acid phosphatase (PAP): monoclonal enzyme-linked immunoassay compared to polyclonal radioimmunoassay.
    Taylor EH; Gadsden RH
    Ann Clin Lab Sci; 1984; 14(1):21-6. PubMed ID: 6364952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostatic acid phosphatase and prostatic specific antigen measured by immunoenzyme assay].
    Fuse H; Akimoto S; Shimazaki J
    Hinyokika Kiyo; 1986 Dec; 32(12):1813-9. PubMed ID: 2435130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
    Hamami G
    Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-antibody immunoenzyme assay for human prostatic acid phosphatase.
    Choe BK; Pontes EJ; Dong MK; Rose NR
    Clin Chem; 1980 Dec; 26(13):1854-9. PubMed ID: 6159996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
    Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
    Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of an immunoenzyme assay of the prostate-specific acid phosphatase (PAP) (E.C.3.1.3.2.) in prostatic carcinoma. Methods and initial clinical results].
    Bauer HW; Schmiedt E
    Urologe A; 1983 Sep; 22 Suppl():367-71. PubMed ID: 6195796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The significance of serum gamma-seminoprotein in prostatic cancer].
    Ishikawa S; Tozuka K; Ishiyama S; Goto K; Ohba S; Tokue A; Yonese Y; Kamachi S; Sakurabayashi I; Kawai T
    Hinyokika Kiyo; 1985 Jun; 31(6):961-7. PubMed ID: 2414979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Purification and determination of human prostate specific antigen in the serum].
    Ogawa Y; Morikawa J; Ohsawa R; Machida T; Miki M; Yanagisawa M
    Radioisotopes; 1984 May; 33(5):273-8. PubMed ID: 6206524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
    Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
    J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase.
    Foti AG; Cooper JF; Herschman H; Malvaez RR
    N Engl J Med; 1977 Dec; 297(25):1357-61. PubMed ID: 73133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.